SGLT2 Inhibitor-Associated Euglycemic DKA: Do Not Be Reassured by Glucose
Overview and Definition
- SGLT2 inhibitor-associated euglycemic DKA is a form of diabetic ketoacidosis in which blood glucose remains below 200 mg/dL.
- The core clinical trap is allowing a normal or mildly elevated glucose result to delay ketone and acid-base evaluation.
- This syndrome is increasingly recognized as SGLT2 inhibitor use becomes more widespread.
Pathophysiology
- SGLT2 inhibitors promote glucosuria, lowering measured serum glucose independently of ketone status.
- Ketogenesis and volume depletion continue despite euglycemia.
- The dissociation between glucose and ketone levels makes this presentation deceptive.
Clinical Presentation
Suspect euglycemic DKA in any patient taking an SGLT2 inhibitor who presents with:
- Nausea and vomiting
- Abdominal pain
- Malaise and fatigue
- Deep or rapid breathing, including Kussmaul respirations
- Signs of dehydration
- Altered mental status
- Unexplained metabolic acidosis
Diagnostic Approach
Initial Testing
- Send blood beta-hydroxybutyrate.
- Send a venous or arterial blood gas.
Adult Three-Part DKA Criteria
- Diabetes history or glucose of at least 200 mg/dL
- Ketosis
- Metabolic acidosis
Euglycemic DKA Specifics
- The same ketosis and acidosis criteria apply.
- Glucose is below 200 mg/dL.
- Beta-hydroxybutyrate of 3.0 mmol/L or higher supports DKA.
- A pH below 7.30 or bicarbonate below 18 mmol/L establishes the acidotic component.
Precipitating Factors to Assess
- Insulin reduction or omission
- Fasting or poor oral intake
- Acute illness
- Dehydration
- Very-low-carbohydrate diet
- Alcohol excess
- Surgery or another metabolic stressor
Management
Immediate Actions
- Stop the SGLT2 inhibitor on admission.
Fluid Resuscitation
- Administer intravenous crystalloid fluids.
- Adjust volume and rate based on cardiac and renal status.
- Monitor for fluid overload.
Electrolyte Management
- Use potassium-guided replacement throughout treatment.
- If potassium is below 3.5 mmol/L, replace potassium before starting insulin.
- Monitor potassium frequently.
Insulin Therapy
- Start intravenous insulin according to the local DKA protocol.
- Do not withhold insulin because glucose is normal.
- Start 5% to 10% dextrose early when needed.
- Dextrose permits continued insulin administration to suppress ketogenesis despite euglycemia.
- 10% dextrose may be required in many cases.
Treat the Precipitant
- Identify and manage the underlying trigger, such as infection or missed insulin.
Monitoring and Resolution Criteria
Parameters to Follow
- Blood glucose
- Serum potassium
- pH or bicarbonate
- Beta-hydroxybutyrate
Resolution Criteria for DKA
- Ketones below 0.6 mmol/L
- Venous pH of at least 7.30 or bicarbonate of at least 18 mmol/L
Critical Reminders
- Do not stop insulin because glucose is normal.
- Do not use anion-gap closure as the sole endpoint for resolution.
- The beta-hydroxybutyrate trend is the most reliable marker of ketone clearance.
Key Takeaway
Euglycemic DKA is real DKA. A normal glucose level does not exclude the diagnosis. In any patient taking an SGLT2 inhibitor who presents with nausea, vomiting, or unexplained acidosis, always check a ketone level and blood gas regardless of the glucose reading. Early recognition prevents dangerous delays in insulin and dextrose therapy.
Clinical treatment should follow the institution's current DKA protocol and account for the patient's cardiac, renal, and electrolyte status.
